11.02
+3.86%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bioventus
From its filings with the US Securities and Exchange Commission
Bioventus is based in Durham, North Carolina and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BVS. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $568.1m and net income of $22.7m. At that date it held total assets of $683.6m and shareholders' equity of $184.1m. By region, U.S. accounted for 88.4%, followed by International at 11.6%.
We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing musculoskeletal challenges through a diverse portfolio of high-quality, innovative, and clinically-proven solutions. We manage our business through two reporting segments, U.S. and International, which accounted for 88% and 12%, respectively, of our total net sales during the fiscal year ended December 31, 2025.
Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments & PRP (“Pain Treatments”), (ii) Surgical Solutions and (iii) Restorative Therapies.
1)Strengthen our leading positions in our core markets. We are focused on continued market share growth of our differentiated HA, BGS and Fracture Care products, which account for the majority of our sales today, through targeted high-potential account execution. This will provide investment for the continued expansion of our Ultrasonics and International businesses and enable growth in our emerging markets in PNS and PRP.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 11 Feb 2021
- Employees
- 930
- Website
- bioventus.com ↗
- Head office
- 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC, 27703
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. William HawkinsNon-Executive Independent Chairman of the Board$287,999
- Mr. Robert ClaypoolePresident, Chief Executive Officer, Director, since 2024$6.4m
- Mr. Mark SingletonChief Financial Officer, Senior Vice President$2.1m
- Ms. Katrina ChurchSenior Vice President, Chief Compliance Officer
- Mr. Anthony D'adamioSenior Vice President, General Counsel$1.6m
- Mr. John BartholdsonIndependent Director$247,999
- Mr. Patrick BeyerIndependent Director$237,999
- Mr. Philip CowdyIndependent Director
- Ms. Mary LadoneIndependent Director$247,500
- Ms. Michelle Mcmurry-HeathIndependent Director$237,999
- Mr. Guido NeelsIndependent Director$235,699
- Mr. Guy NohraIndependent Director$233,999
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 4
- Social
- 69
- Governance
- 47
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bioventus Inc possesses several strengths that contribute to its success in the market:
Weaknesses
- Despite its strengths, Bioventus Inc also faces certain weaknesses that need to be addressed:
Opportunities
- Bioventus Inc can leverage the following opportunities to enhance its market position:
Threats
- Bioventus Inc should be mindful of the following threats that could impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.